tirapazamine
/ Raygene Pharmaceuticals
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 07, 2025
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
(clinicaltrials.gov)
- P2/3 | N=300 | Recruiting | Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor
February 26, 2025
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) with CTACE for Intermediate-stage Liver Cancer.
(clinicaltrials.gov)
- P2/3 | N=300 | Not yet recruiting | Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd
New P2/3 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor
February 27, 2025
Evaluate the Effect of Tirazamine on Primary Liver Cancer.
(clinicaltrials.gov)
- P1/2 | N=16 | Terminated | Sponsor: Zhejiang Raygene Pharmaceuticals Co., Ltd
New P1/2 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1